These results establish REN001 as a potential therapy for VLCADD as enhanced expression may provide a therapeutic increase in total VLCAD activity, but suggest the need for mutation-specific treatment augmented by other treatment measures. The gene discussed is ACADVL; the disease is very long chain acyl-CoA dehydrogenase deficiency.